Ultra-Hypofractionated Radiotherapy Noninferior for Prostate Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 8, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, May 8, 2025 -- Ultra-hypofractionated (UHF) radiotherapy delivered over two weeks is noninferior to conventionally fractionated (CF) radiotherapy delivered over eight weeks for localized prostate cancer up to 10 years, according to a study presented at the annual meeting of the European Society for Radiotherapy and Oncology, held from May 2 to 6 in Vienna.

Per Nilsson, Ph.D., from Skåne University Hospital in Lund, Sweden, and colleagues presented the 10-year efficacy and toxicity outcomes for UHF versus CF radiotherapy for men with intermediate- to high-risk localized prostate cancer. The per-protocol population included 1,180 men who were randomly assigned to UHF (42.7 Gy in seven fractions over 2.5 weeks) or CF radiotherapy (78.0 Gy in 39 fractions over eight weeks).

The researchers found that 178 and 205 primary outcome events (failure-free survival [FFS]) occurred in the UHF and CF groups, respectively, at a median follow-up of 10.6 years. For FFS, the adjusted hazard ratio was 0.84 (95 percent confidence interval, 0.69 to 1.03), confirming noninferiority. Up to approximately six years, the Kaplan-Meier curves were similar, after which they diverged, favoring UHF. At 10 years, the difference was significant. The two groups had similar overall survival, which was 81 and 79 percent in the UHF and CF groups, respectively, at 10 years. The cumulative incidence of prostate cancer-specific death was identical, at 4 percent at 10 years. Freedom from androgen-deprivation therapy did not differ significantly between the groups and was 77 and 75 percent in the UHF and CF groups, respectively, at 10 years. There were no statistically significant differences in late genitourinary and gastrointestinal toxicity between the groups.

"Delivering fewer, higher doses over a shorter period works just as well as the standard approach -- not just in theory, but in real-world clinical practice," Nilsson said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-09 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords